Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Priority review granted with PDUFA target action date of April 30, 2024BRISBANE, Calif., Oct. 30, 2023 -- Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to...

Related Keywords

Australia ,United States ,California ,Brisbane ,Queensland ,Canada ,Jeremy Bender ,Laura Cooper ,Oncology Consortium ,Head Of Communications ,Exchange Commission ,Drug Administration ,European Commission ,Company On Linkedin ,One Biopharmaceuticals ,New Drug Application ,Prescription Drug User Fee Act ,Pediatric Disease Priority Review Voucher ,Pacific Pediatric Neuro Oncology Consortium ,Response Asessment ,Neuro Oncology High Grade Glioma ,Response Assessment ,Pediatric Neuro Oncology Low Grade Glioma ,Neuro Oncology Low Grade Glioma ,Pacific Pediatric Neuro Oncology ,Breakthrough Therapy ,Rare Pediatric Disease ,Orphan Drug ,Day One ,Private Securities Litigation Reform Act ,Sci Advisors ,Markets ,